DE3687736T2 - Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung. - Google Patents

Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.

Info

Publication number
DE3687736T2
DE3687736T2 DE8686307735T DE3687736T DE3687736T2 DE 3687736 T2 DE3687736 T2 DE 3687736T2 DE 8686307735 T DE8686307735 T DE 8686307735T DE 3687736 T DE3687736 T DE 3687736T DE 3687736 T2 DE3687736 T2 DE 3687736T2
Authority
DE
Germany
Prior art keywords
monoclonal antibodies
breast cancer
human breast
hybridome
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8686307735T
Other languages
English (en)
Other versions
DE3687736D1 (de
Inventor
David Barratt Ring
Arthur Edward Frankel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Oncology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Oncology Corp filed Critical Cetus Oncology Corp
Publication of DE3687736D1 publication Critical patent/DE3687736D1/de
Application granted granted Critical
Publication of DE3687736T2 publication Critical patent/DE3687736T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/804—Drug, bio-affecting and body treating compositions involving IgG3, IgG4, IgA, or IgY
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y10S424/807—Monoclonal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Geophysics And Detection Of Objects (AREA)
  • Navigation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE8686307735T 1985-10-07 1986-10-07 Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung. Expired - Fee Related DE3687736T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78507685A 1985-10-07 1985-10-07
US06/786,948 US4938948A (en) 1985-10-07 1985-10-11 Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies

Publications (2)

Publication Number Publication Date
DE3687736D1 DE3687736D1 (de) 1993-03-25
DE3687736T2 true DE3687736T2 (de) 1993-05-27

Family

ID=27120360

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686307735T Expired - Fee Related DE3687736T2 (de) 1985-10-07 1986-10-07 Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.

Country Status (13)

Country Link
US (1) US4938948A (de)
EP (1) EP0220858B1 (de)
JP (3) JP2968474B2 (de)
AT (1) ATE85652T1 (de)
AU (1) AU6356986A (de)
CA (1) CA1338706C (de)
DE (1) DE3687736T2 (de)
DK (1) DK478886A (de)
ES (1) ES2053440T3 (de)
FI (1) FI864037A (de)
IL (1) IL80231A (de)
NO (1) NO863974L (de)
NZ (1) NZ217829A (de)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5032521A (en) * 1984-12-05 1991-07-16 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cell surface antigen
AU601379B2 (en) * 1985-11-07 1990-09-13 Trustees Of Columbia University In The City Of New York, The Antigen indicative of human breast cancer and assays based thereon
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US6861511B1 (en) 1986-06-04 2005-03-01 Bayer Corporation Detection and quantification of neu related proteins in the biological fluids of humans
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
NZ222509A (en) * 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US6004761A (en) * 1986-11-19 1999-12-21 Sanofi Method for detecting cancer using monoclonal antibodies to new mucin epitopes
US4863726A (en) * 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
US5084266A (en) * 1988-02-03 1992-01-28 The University Of Melbourne Method for tumor imaging utilizing a labelled tumor specific antibody and a non-tumor reactive antibody
US5681543A (en) * 1988-02-29 1997-10-28 Shering Aktiengesellschaft Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
US5811267A (en) * 1990-10-29 1998-09-22 Chiron Corporation Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens
US5849877A (en) * 1990-10-29 1998-12-15 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5948647A (en) * 1990-10-29 1999-09-07 Chiron Corporation Nucleic acids encoding antigen-binding sites specific for cancer antigens
US5292524A (en) * 1991-09-06 1994-03-08 California Institute Of Technology Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus
AU675929B2 (en) * 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US7255851B2 (en) * 1994-07-01 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US20030086922A1 (en) * 1994-12-02 2003-05-08 David B. Ring Method of promoting an immune response with a bispecific antibody
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
GB9906380D0 (en) * 1999-03-19 1999-05-12 Melvin William T Monoclonal antibodies specific for cypibi
FR2811323B1 (fr) * 2000-07-07 2006-10-06 Fuma Tech Gmbh Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
DE10141937A1 (de) * 2001-08-28 2003-03-27 Alfred Schmidt Markierung der Aromatase
EP2131198B1 (de) 2001-09-20 2013-03-27 Board of Regents, The University of Texas System Messung der zirkulierenden therapeutischen Antikörper-, Antigen- und Antigen-/Antikörperkomplexe unter Verwendung enzymgekoppelter Immunadsorptionstests
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
US20040180344A1 (en) * 2003-03-14 2004-09-16 Morris David W. Novel therapeutic targets in cancer
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
JP2005520543A (ja) 2002-03-21 2005-07-14 サイグレス ディスカバリー， インコーポレイテッド 癌における新規組成物および方法
AU2003304195B8 (en) 2002-07-15 2008-08-28 Board Of Regents, The University Of Texas System Combinatorial protein library screening by periplasmic expression
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
US7767387B2 (en) * 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
CA2516138A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
US20070218071A1 (en) * 2003-09-15 2007-09-20 Morris David W Novel therapeutic targets in cancer
US20070281896A1 (en) * 2003-09-30 2007-12-06 Morris David W Novel compositions and methods in cancer
CN1925871A (zh) * 2004-01-27 2007-03-07 南加州大学 聚合物结合的抗体癌症治疗剂
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
AU2005287090A1 (en) 2004-09-18 2006-03-30 Department Of Veterans Affairs Therapeutic agents targeting the NCca-ATP channel and methods of use thereof
AU2005290238A1 (en) 2004-09-18 2006-04-06 Department Of Veterans Affairs Therapeutic agents trageting the NCCa-ATP channel and methods of use thereof
PT2645106T (pt) 2005-04-04 2017-09-18 Biogen Ma Inc Método para avaliar uma resposta imune a um agente terapêutico
EP1865981A2 (de) 2005-04-07 2007-12-19 Chiron Corporation Cacna1e in der diagnose und nachweis von sowie als therapeutisches mittel gegen krebs
EP1871911A2 (de) 2005-04-07 2008-01-02 Chiron Corporation Gene in verbindung mit krebs (prlr)
US8124351B2 (en) 2005-11-18 2012-02-28 Board Of Regents, The University Of Texas System Quantification of fusion proteins and their activity from chromosomal translocation
WO2008005429A2 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
ATE555128T1 (de) 2006-11-30 2012-05-15 Res Dev Foundation Verbesserte immunglobulin-bibliotheken
WO2008089103A2 (en) 2007-01-12 2008-07-24 University Of Maryland, Baltimore Targeting ncca-atp channel for organ protection following ischemic episode
KR100855299B1 (ko) * 2007-02-16 2008-08-29 건국대학교 산학협력단 인간 ｉｌ-32 특이 항원결정기를 갖는 단일클론항체,특이항체분비 융합 세포주 및 항체들을 이용한 ｉｌ-32측정법
DK2155789T3 (da) 2007-05-01 2013-10-21 Res Dev Foundation Immunoglobulin-Fc-biblioteker
CA2691539C (en) * 2007-06-21 2014-08-26 Angelica Therapeutics, Inc. Modified toxins
WO2009020923A1 (en) 2007-08-03 2009-02-12 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
CA2711499C (en) 2008-01-10 2018-09-25 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
US8470314B2 (en) * 2008-02-29 2013-06-25 Angelica Therapeutics, Inc. Modified toxins
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
CA2743057C (en) 2008-11-07 2019-11-26 Research Development Foundation Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
CA2745111A1 (en) 2008-12-03 2010-06-10 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
AU2010303156B2 (en) 2009-10-11 2016-02-04 Biogen Ma Inc. Anti-VLA-4 related assays
US9260517B2 (en) 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
US9309322B2 (en) 2010-11-12 2016-04-12 Scott & White Healthcare (Swh) Antibodies to tumor endothelial marker 8
AU2012214643B2 (en) 2011-02-07 2016-12-15 Research Development Foundation Engineered immunoglobulin Fc polypeptides
HUE036172T2 (hu) 2011-04-01 2018-06-28 Immunogen Inc Eljárások a hatékonyság növelésére a FOLR1 rákkezelésénél
US8663637B2 (en) 2011-08-05 2014-03-04 Research Development Foundation Methods and compositions for modulation of Olfml3 mediated angiogenesis
US9556281B2 (en) 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
ES2731757T3 (es) 2012-03-20 2019-11-18 Biogen Ma Inc Anticuerpos neutralizantes de JCV
CN104703622B (zh) 2012-04-26 2017-05-24 芝加哥大学 与金黄色葡萄球菌疾病期间抵消凝固酶活性的抗体相关的组合物和方法
MX2014013678A (es) 2012-05-10 2015-02-04 Massachusetts Inst Technology Agentes para neutralizacion de influenza.
KR20200102524A (ko) 2012-08-07 2020-08-31 메사추세츠 인스티튜트 오브 테크놀로지 항-뎅기 바이러스 항체 및 이들의 용도
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
EP2912064B1 (de) 2012-10-24 2019-04-24 Research Development Foundation Jam-c-antikörper und verfahren zur behandlung von krebs
US9388397B2 (en) 2013-02-15 2016-07-12 Research Development Foundation Deimmunized gelonin molecules and therapies
JP2016519651A (ja) 2013-03-15 2016-07-07 アンジェリカ セラピューティックス，インク． 改質された毒素
MX359794B (es) 2013-03-15 2018-10-10 Intrinsic Lifesciences Llc Anticuerpos anti-hepcidina y usos de los mismos.
ES2935257T3 (es) 2013-03-15 2023-03-03 Univ Chicago Métodos y composiciones relacionadas con la actividad de las células T
WO2014151683A1 (en) 2013-03-15 2014-09-25 Bayer Healthcare Llc Gla domains as targeting agents
WO2014197723A2 (en) 2013-06-05 2014-12-11 Massachusetts Institute Of Technology Human adaptation of h7 ha
CN105555303A (zh) 2013-06-28 2016-05-04 贝勒研究院 用于多发性硬化症的树突细胞asgpr靶向免疫治疗剂
CN106659909B (zh) 2013-08-21 2022-01-11 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
KR102585409B1 (ko) 2013-08-30 2023-10-05 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 항체 및 분석
WO2015070009A2 (en) 2013-11-08 2015-05-14 The Board Of Regents Of The University Of Texas System Vh4 antibodies against gray matter neuron and astrocyte
AU2015204503B2 (en) 2014-01-13 2020-07-09 Baylor Research Institute Novel vaccines against HPV and HPV-related diseases
JP6908381B2 (ja) 2014-01-29 2021-07-28 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１−ｃ／細胞外ドメイン（ｍｕｃ１−ｃ／ｅｃｄ）に対する抗体
JP6707455B2 (ja) 2014-02-11 2020-06-10 マサチューセッツ インスティテュート オブ テクノロジー 新規フルスペクトル抗デング抗体
RU2744836C2 (ru) 2014-05-08 2021-03-16 Новодиакс, Инк. Прямой иммуногистохимический анализ
WO2015179435A1 (en) 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
AU2015306621B2 (en) 2014-08-27 2021-05-06 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses
WO2016049036A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
US10457737B2 (en) 2015-02-09 2019-10-29 Research Development Foundation Engineered immunoglobulin Fc polypeptides displaying improved complement activation
CA2976074A1 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
EP3262411B1 (de) 2015-02-25 2022-04-06 Vanderbilt University Antikörper-vermittelte neutralisierung von marburg-virus
WO2017040380A2 (en) 2015-08-28 2017-03-09 Research Development Foundation Engineered antibody fc variants
JP6987068B2 (ja) 2015-11-09 2021-12-22 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia 癌マーカーおよび治療標的としてのグリピカン２
AU2016365318B2 (en) 2015-12-02 2024-04-18 Board Of Regents, The University Of Texas System Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
KR20180100122A (ko) 2015-12-02 2018-09-07 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
EP3383418B1 (de) 2015-12-04 2021-10-20 Board of Regents, The University of Texas System Slc45a2-peptide für immuntherapie
AU2017224122B2 (en) 2016-02-26 2024-04-11 The Board Of Regents Of The University Of Texas System Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
EP3943508B1 (de) 2016-03-29 2024-01-10 Board Of Regents, The University Of Texas System Zweifach funktionale antikörper, die spezifisch für glykosyliertes pd-l1 sind, und verfahren zur verwendung davon
EP3436480A4 (de) 2016-03-30 2019-11-27 Musc Foundation for Research Development Verfahren zur behandlung und diagnose von krebs durch targeting von glycoprotein a repetitions predominant (garp) und zur effektiven immuntherapie allein oder in kombination
US11559590B2 (en) 2016-07-01 2023-01-24 The General Hospital Corporation Granzyme B directed imaging and therapy
JP2019528251A (ja) 2016-07-20 2019-10-10 エスティーキューブ，インコーポレイテッド グリコシル化ｐｄ−ｌ１に結合する抗体の組合せを使用するがんの処置および治療の方法
WO2018126183A2 (en) 2016-12-29 2018-07-05 The General Hospital Corporation Her3 peptides for imaging and radiotherapy
EP3630834A1 (de) 2017-05-31 2020-04-08 STCube & Co., Inc. Verfahren zur behandlung von krebs mit antikörpern und molekülen, die immunspezifisch an btn1a1 binden
EP3630835A1 (de) 2017-05-31 2020-04-08 STCube & Co., Inc. Antikörper und moleküle, die immunspezifisch an btn1a1 binden, und therapeutische verwendungen davon
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
US10759865B2 (en) 2017-08-22 2020-09-01 Eyal Levit Treatment of diabetes mellitus
WO2019040780A1 (en) 2017-08-25 2019-02-28 Five Prime Therapeutics Inc. ANTI-B7-H4 ANTIBODIES AND METHODS OF USE
CN111051500A (zh) 2017-09-05 2020-04-21 角斗士生物科学公司 有效载荷递送至干细胞
US11464784B2 (en) 2017-09-15 2022-10-11 The Regents Of The University Of California Inhibition of aminocylase 3 (AA3) in the treatment of cancer
US11525002B2 (en) 2017-10-11 2022-12-13 Board Of Regents, The University Of Texas System Human PD-L1 antibodies and methods of use therefor
US11851478B2 (en) 2018-01-05 2023-12-26 Vanderbilt University Antibody-mediated neutralization of chikungunya virus
BR112020017925A2 (pt) 2018-03-02 2020-12-22 Five Prime Therapeutics, Inc. Anticorpos contra b7-h4 e métodos de uso dos mesmos
WO2019182896A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
JP2022500084A (ja) 2018-09-13 2022-01-04 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 新規のｌｉｌｒｂ４抗体およびその使用
EP4219550A1 (de) 2018-11-02 2023-08-02 Oklahoma Medical Research Foundation Monoklonale antikörper gegen etld1 und verwendungen davon
WO2020113084A1 (en) 2018-11-28 2020-06-04 Oregon Health & Science University Therapeutic factor xii antibody
WO2020167989A1 (en) 2019-02-13 2020-08-20 Cytosite Biopharma Inc. Granzyme b directed imaging and therapy
EP3999546A1 (de) 2019-07-19 2022-05-25 The Children's Hospital of Philadelphia Chimäre antigenrezeptoren mit glypican-2-bindungsdomänen
JP2022541652A (ja) 2019-07-26 2022-09-26 ヴァンダービルト ユニバーシティ エンテロウイルスｄ６８に対するヒトモノクローナル抗体
JP2022549504A (ja) 2019-09-26 2022-11-25 エスティーキューブ アンド カンパニー グリコシル化ｃｔｌａ－４に対して特異的な抗体およびその使用方法
WO2021072277A1 (en) 2019-10-09 2021-04-15 Stcube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
IL295310A (en) 2020-02-11 2022-10-01 Univ Vanderbilt Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
PL4045533T3 (pl) 2020-03-26 2024-04-15 Vanderbilt University Ludzkie przeciwciała monoklonalne przeciwko ciężkiemu ostremu zespołowi oddechowemu wywołanemu koronawirusem 2 (sars-cov-2)
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
GB202105804D0 (en) 2020-11-20 2021-06-09 Univ Cape Town Use of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan
GB2603166A (en) 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
WO2022192134A1 (en) 2021-03-08 2022-09-15 Immunogen, Inc. Methods for increasing efficacy of immunoconjugates targeting adam9 for the treatment of cancer
GB202201137D0 (en) 2022-01-28 2022-03-16 Thelper As Therapeutic and diagnostic agents and uses thereof
WO2023192976A1 (en) 2022-04-01 2023-10-05 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
GB202204813D0 (en) 2022-04-01 2022-05-18 Bradcode Ltd Human monoclonal antibodies and methods of use thereof
WO2023239940A1 (en) 2022-06-10 2023-12-14 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof
WO2024040020A1 (en) 2022-08-15 2024-02-22 Absci Corporation Quantitative affinity activity specific cell enrichment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
CA1215331A (en) * 1983-03-04 1986-12-16 Tsann M. Chu Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
WO1985001442A1 (en) * 1983-09-28 1985-04-11 Summa Medical Corporation Lectin composition and method for diagnosis of cancer
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
EP0160446B1 (de) * 1984-05-01 1992-06-17 Ciba Corning Diagnostics Corp. Brusttumorassoziiertes Antigen und monoklonale Antikörper dazu
US4695538A (en) * 1984-06-01 1987-09-22 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cell surface antigens
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies

Also Published As

Publication number Publication date
EP0220858A3 (en) 1988-08-03
FI864037A0 (fi) 1986-10-06
CA1338706C (en) 1996-11-12
NZ217829A (en) 1989-06-28
DK478886D0 (da) 1986-10-07
FI864037A (fi) 1987-04-08
IL80231A (en) 1991-08-16
JP2968474B2 (ja) 1999-10-25
EP0220858A2 (de) 1987-05-06
AU6356986A (en) 1987-04-09
ATE85652T1 (de) 1993-02-15
DE3687736D1 (de) 1993-03-25
ES2053440T3 (es) 1994-08-01
NO863974L (no) 1987-04-08
DK478886A (da) 1987-04-08
EP0220858B1 (de) 1993-02-10
JPH08266273A (ja) 1996-10-15
JP2000000092A (ja) 2000-01-07
US4938948A (en) 1990-07-03
JP2000000091A (ja) 2000-01-07
NO863974D0 (no) 1986-10-06

Similar Documents

Publication Publication Date Title
DE3687736T2 (de) Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.
DE3483054D1 (de) Monoklonale antikoerper gegen humane brustkarzinomzellen und ihre verwendung in der diagnose und therapie.
ES8705975A1 (es) Un metodo de deteccion o localizacion de celulas de carcinoma humano.
DE3382764D1 (de) Humane-humane hybridomas für neoplasmen.
DE3887675D1 (de) Antikörper.
DK40885D0 (da) Monoklonalt antistof, fremgangsmaade og celle til fremstilling deraf,fremgangsmaade til fremstilling af cellen og farmaceutisk praeparat indeholdende det monoklonale antistof
NL300040I2 (nl) Monoklonale antilichamen tegen borstkanker bij de mens, de bereiding en het gebruik ervan, en hybridoma's voor de produktie en bereiding ervan.
NZ222309A (en) Antibodies (including chimeric antibodies) to a human tumour antigen, polynucleotides encoding them, detection of the antigen by immunoassay and imaging methods and also cell killing methods
DE69522689T2 (de) Zellzyklus-unabhängige, gliomaoberflach-spezifische, menschliche monoklonale antikörper
EP0232871A3 (de) Menschlicher monoklonaler Antikörper, Hybridoma zu seiner Herstellung und seine Verwendung
ES8504463A1 (es) Un metodo para la preparacion de anticuerpos monoclonales humanos especificos para las celulas neoplasicas
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
EP0155172A3 (de) Monoklonale Antikörper gegen menschlichen Lungenkrebs
DE3784364T2 (de) Tumorassoziiertes antigen.
JPS6444856A (en) Anti-cancer antigen anti-serum
EP0278160A3 (de) Menschliche monoklonale Antikörper gegen Krebs, Hybridoma-Zellinien, die sie herstellen und ihre Anwendungen
ATE84069T1 (de) Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist.
JPS6439992A (en) Monoclonal antibody

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CHIRON CORP. (N.D.GES.D. STAATES DELAWARE), EMERYV

8339 Ceased/non-payment of the annual fee